The CHART (Continuous Hyperfractionated Accelerated Radiation Therapy) trials in head and neck and non-small cell carcinoma of the bronchus, which began in January 1990, closed in March 1995 when 918 and 563 patients respectively had been accrued. Patient characteristics were balanced between the treatment groups and protocol treatment was given in 89% of cases. Early mucosal reactions occurred sooner with CHART and were more troublesome than with conventional therapy. They settled quickly and so far no difference in long-term morbidity has been observed. L'hermitte's Syndrome has been observed in 11 patients in both arms of the study. There has been no radiation myelitis. There has been a 10% improvement in survival in the bronchus trial and a small statistically nonsignificant improvement in disease free interval in the head and neck patients. In both trials there is a trend for those with more advanced disease (T3 and T4) to benefit more from CHART. Interim results appear to confirm the hypothesis that tumour cell repopulation may occur during treatment and the treatment should therefore be completed in the shortest possible overall time. The implications of this for normal tissue reactions will be discussed. Detailed data on early and late normal tissue reactions will be presented and the use of this data for further hypothesis testing will be discussed.
Quantifying subclinical metastatic burden and its response to elective treatments H Rodney Withers, MD, DSc Radiation Oncology and JCCC, UCLA, Los Angeles, CA 90095-1714, USA. Although no patient is cured of cancer if the primary tumor is not controlled, a major improvement in survival has stemmed from elective treatment of subclinical disease as an adjuvant to curative treatment of the primary. Historically this began with elective radiotherapy of regional disease and was later extended to chemotherapy for systemic metastases. By definition, the quantitative assessment of the extent of metastatic subclinical disease is impossible, and appropriately, elective treatment is usually based on an implicit assumption that patients at risk harbor a maximal metastatic cell burden.
If for a certain type and stage(s) of cancer a proportion of patients have overt (clinically detectable) metastases at presentation, and a proportion will never develop metastases if the primary tumor is controlled, then the remainder, that is, the proportion who show no evidence of metastases at presentation but who will subsequently develop them, can be assumed to harbor a metastatic cell burden distributed between 1 and N, where N is the number of metastatic tumor clonogens necessary to become detectable. Because of an exponential growth pattern of metastases and a wide variation among patients in the size of the primary at the time of initiation of metastases, a reasonable first assumption is that there was a uniform distribution of the logarithm of metastatic cell numbers among patients with subclinical metastases. The dose response of subclinical disease is consistent with this assumption leading to the possibility of analyzing the biological basis for the dose responses of subclinical metastases. This investigation was supported by PHS grant number CA-31612 awarded by the National Cancer Institute, DHHS. 100 years ago, when R6ntgen discovered x-rays, epidemiology was effectively limited to the study of infectious disease and the hazards of ionizing radiation were initially discovered through clinical acumen and laboratory experiment. Such methods quickly led to the recognition of acute effects and gradually over 50 years to the recognition that ionizing radiation could also produce genetic mutations, chronic anaemia, and cancers in many sites. Cancer, however, was generally thought to be produced only when the dose was large enough to cause macroscopic tissue damage. An occupational hazard of leukaemia alone gave cause to think that cancer might also be produced by the accumulation of small doses.
Following the explosion of the atomic bombs the situation changed and attempts began to be made to obtain quantitative estimates of risk, and it was not until after the explosion of the hydrogen bomb in 1954 that they were organized in such a way as to enable small risks to be estimated effectively. The results now available from many sources relating to genetic mutations, damage to the fetal brain, the risk of cancer, and an increased rate of ageing are reviewed and their limitations discussed. The formation of nitric oxide (NO) from L-arginine is now recognised as a ubiquitous pathway involved in a variety of physiological functions. The synthesis of NO by vascular endothelium is responsible for the vascular tone that is essential for the regulation of blood pressure. In the central nervous system NO is a neurotransmitter that underlies a number of functions, including the formation of memory. In the periphery, there is a widespread network of nerves, previously recognised as nonadrenergic and noncholinergic, that operate through an NO-dependent mechanism to mediate some forms of neurogenic vasodilatation and regulate various gastrointestinal, respiratory, and genitourinary tract functions. Nitric oxide also contributes to the control of platelet aggregation and the regulation of cardiac contractility. These physiological effects of NO are all mediated by the action of a constitutive NO synthase and subsequent activation by NO of the soluble guanylate cyclase. In addition, NO is produced in large quantities by an inducible NO synthase (iNOS) during host defence and immunological reactions. Because it has cytotoxic properties and is generated by activated macrophages, NO A clonogenic assay was used to measure the radiation sensitivity of monolayer, exponentially growing cultures of human colonic tumour cell lines (Widr and HT29) and a normal rat intestinal cell line (IEC6) both with and without a 6 h post-irradiation delay to allow for repair of potentially lethal damage. TGF#3 (5 ng ml-1) was added to the cultures either before, during or after irradiation. Treatment with TGF/3 for 24 h before irradiation significantly increased the radiosensitivity of the Widr cell line only when they were allowed the 6 h recovery period. The same protocol had no effect on the radiosensitivity of the HT29 cell line but was able to reduce the radiosensitivity of the normal cell line, IEC6. These are indicated as the surviving fraction (SF) at 7.5 Gy in the table below. Flow cytometric cell cycle analysis at all stages of the experiment showed that the number of IEC6 cells in S-phase was considerably reduced by the preirradiation treatment whereas there was no effect on There is substantial evidence that hypoxic tumour cells compromise the effect of irradiation (1, 2) . In this report oxygenation status (tumour p02) was correlated with radiation response in 108 C3H mouse mammary carcinomas and in 36 patients with advanced squamous cell carcinomas of head and neck. Tumour p02 was measured by polarographic oxcygen electrodes (Eppendorf, Germany) and evaluated as the median PO2, the percentage of PO2 values S 2.S mmHg and S mmHg. In mice group one (n = 52) tumour p02 was hypothesized to predict outcome of radiation response. The median value of the three oxygenation parameters was related to the probability of tumour control after 55 This treatment is now in Phase III trial. We would welcome referral of all eligible patients. 1991; 78, 326). These changes are due, at least in part, to the presence of a circulating vasoconstrictor (Carter R et al. Br. J. Cancer, 1994; 69, 1025). To determine whether these haemodynamic changes are also associated with structural changes in splanchnic vessels, we have measured wall dimensions in mesenteric resistance arteries from rats with and without hepatic tumours. The small bowel was isolated and harvested 23-28 days following intra-hepatic inoculation of either HSN sarcoma cells or a control solution and perfused via the superior mesenteric artery at 90-100 mmHg pressure, using a 2.5% buffered glutaraldehyde solution. The samples, taken from 13 tumour-bearing and 13 control rats, were coded so that the measurements could be performed in a blind manner. Tissue blocks were embedded in wax and sectioned so that the vessels of interest were cut in transverse section. The vessels were stained with haematoxylin and eosin and viewed using an image analysis system which allowed lumen diameter as well as median and wall thickness to be measured. Average media-to-lumen and wall-to-lumen ratios were calculated for each animal and compared for each group using a Mann-Whitney U test. Results are expressed as median value (interquartile range). Media-to-lumen and wall-to-lumen ratios were significantly increased in tumour-bearing animals compared with controls, demonstrating that the presence of liver tumour can alter the structure of extrahepatic blood vessels. These findings are consistent with the changes in splanchnic blood flow which occur in vivo in liver cancer. Ongoing studies will determine whether increased wall thickness is due to smooth muscle hyperplasia or hypertrophy or to vessel remodelling. Tumor angiogenesis is an important factor for tumor growth and metastasis. Although some recent reports suggest that microvessel counts in non small cell lung cancer are related to a poor disease outcome, the results were not conclusive and were not compared with other molecular prognostic markers. In the present study we assessed the vascular grade in 107 (T1,2-NO,1) operable non small cell lung carcinomas using the JC70 monoclonal antibody to CD3 1. Three different vascular grades were defined with appraisal by eye and Chalkley counting -high (Chalkley score 7-12), medium (5-6) and low (2-4) vascular grade. There was a significant correlation between eye appraisal and Chalkley counting (p <0.0001). Vascular grade was not related to histology, grade, proliferation index (Ki67), EGFR or p53 expression. Tumors from younger patients had a higher degree of angiogenesis (p = 0.05). Apart from the vascular grade, none of the other examined factors was statistically related to lymph-node metastasis (p <0.0001). A univariate analysis of survival showed that vascular grade was the most significant prognostic factor (p = 0.0004) followed by N-stage (p = 0.001). In a multivariate analysis, N-stage and vascular grade were not found to be independent prognostic factors since both were strongly related to each other. Excluding Nstage, the vascular grade was the only independent prognostic factor (p = 0.007). Kaplan-Meier survival curves showed a statistically significant worse prognosis of patients with high vascular grade. No difference was observed between low and medium vascular grade. Our data suggest that angiogenesis in operable non small cell lung cancer is a major prognostic factor for survival and, among the tested parameters, is the only factor related to cancer cell migration to lymph-nodes. We are currently evaluating the relationship of angiogenesis to Bcl-2, c-erbB-2 and thymidine phosphorylase expression in NSCLC. The integration of vascular grading in clinical trials on adjuvant chemotherapy and/or radiotherapy may substantially contribute to defining groups of operable patients that would benefit from cytotoxic treatment. The aim of this study was to determine whether CRC incidence differed in areas of high and low socioeconomic deprivation in N. Ireland.
The Northern Ireland Colorectal Cancer Register provided details on all the 1178 newly-diagnosed patients with CRC in our province in 1990 and 1991. We related age, sex, site and Dukes' stage to levels of socioeconomic deprivation. Electoral wards were grouped into quintiles of the population after ranking by the Townsend Deprivation Score. The association between CRC incidence and Townsend Score was studied using Poisson regression analysis.
Age-standardised CRC incidence ranged from 22.5 to 29.9 per 100,000 for men from the least to the most deprived fifth of the population. The trend for females was similar but tended to plateau for the lower socioeconomic quintiles. After adjusting for age and sex, there was a significant association between CRC incidence and socioeconomic deprivation (p = 0.002). The The aim of this study was to determine if a dose-response can be observed in the intravesical treatment of superficial bladder cancer with epirubicin. 100 patients with primary or recurrent pTa or pT1 disease were treated surgically, leaving a marker tumour in the bladder. Following histopathological confirmation of tumour stage, patients were randomized by the method of sealed envelopes to receive 1 mg/ml epirubicin (50 mg in 50 ml saline) or 2 mg/ ml epirubicin (100 mg in 50 ml saline) between 10 and 21 days post-operatively. 3 months later the response of the marker tumour was assessed as complete (no tumour visible either cystoscopically or histopathologically in a biopsy taken at the site of the marker tumour) or as no response (histopathologically confirmed persistence of tumour). The volume of the bladder contents was measured after treatment, and taking into account dilution by urine the mean doses received were 0.7 mg/h/ml (1 mg/ml dose) and 1.4 mg/h/ml (2 mg/ml dose). 43/100 (43%) of the patients responded to the single instillation of epirubicin. Of the patients receiving 1 mg/ml epirubicin, 22/50 (44%) responded, compared to 21/ 50 (42%) of patients receiving 2 mg/ml epirubicin. 5 patients receiving the higher dose experienced bladder irritability to the extent that the instillate could not be retained for the full one hour.
This study does not provide any indication of a doseresponse of superficial bladder cancer to epirubicin. Recent work suggests that the milieu in which the metastatic cell finds itself is crucial to its survival (Frost P, 1992, Lancet, 339: 1458-1461). It has been reported that many patients with advanced disease have an ongoing inflammatory response and there is increasing evidence that this promotes tumour progression. Hepatic arterial 5FU chemotherapy may delay or reverse tumour progression in patients with colorectal liver metastases. However, it may also result in tissue damage and thus enhance the inflammatory response. The overall effect on the inflammatory response has not been demonstrated. This was examined in a cohort of patients with colorectal liver metastases. Patients, of equivalent staging, were grouped according to whether they had yet received hepatic arterial 5FU chemotherapy (n = 13) or not (n = 8). Venous 14 patients with breast cancer stage II-IV (4 with metastatic disease and 10 receiving adjuvant therapy for high risk disease), median age 43 years (range 28-55) underwent a high dose chemotherapy procedure with PBPC rescue. Of the 10 patients receiving adjuvant therapy, the median number of involved axillary lymph nodes was 6 (range 4-11 and all had T2 or T3 tumours).
Induction therapy consisted of cyclophosphamide (Cy)/ Epirubicin (1 patient); 5-fluorouracil/epirubicin/Cy (FEC) (11 patients); doxorubicin (1 patient); doxorubicin followed by intermediate dose cyclophosphamide (1 patient Patients with bladder cancer had significantly higher concentrations of sE-cadherin compared with the control group (P=0.017). No difference was found between the two groups with regard to sE-selection (P=0.403), sVCAM-1 (P=0.942) or sICAM-1 (P=0.092). Levels of sE-cadherin were related to poor histological grade (P = 0.011), number of superficial tumours at presentation (P=0.008) and a positive three-month check cystoscopy in superficial disease (P=0.036). The lowest levels of sE-cadherin were found in patients who presented with solitary low grade tumours who had a negative three-month check cystoscopy. For those patients with muscle-invasive disease, elevated sE-cadherin was not related to the presence of metastatic lesions at presentation. Abnormal E-cadherin expression on the tumour was associated with stage (P = 0.009) and grade (P = 0.03). No correlation was found between high levels of sE-cadherin in sera and an abnormal E-cadherin staining pattern (P = 0.077).
Elevated levels of sE-cadherin can be detected in sera of patients with bladder cancer. Its association with multifocality at presentation and tumour recurrence suggest that it is a serum marker with potential predictive value in determining future tumour behaviour. In this study, we have begun to examine the concept that inhibition of intracellular calmodulin activity will reduce tumour cell invasion though ECM proteins. We 
